Intravenous XXXX increase insulin clearance and action in postmenopausal @entity1 .

@entity172 @entity1 @entity1009 @entity653 @entity53 @entity413
To test the hypothesis that @entity172 alter insulin action, we evaluated the effects of intravenous conjugated @entity172 (CE) on insulin-stimulated steady-state @entity413 infusion rate (SSGIR) and suppression of plasma @entity653 in postmenopausal @entity1 (mean +/- SD; 56 +/- 4 yr; n = 12) not using hormone replacement. SSGIR and @entity653 were measured during a two-stage (8 and 40 mU. m-2. @entity1009 ) hyperinsulinemic euglycemic clamp on 2 days, with or without a 2.5-mg intravenous CE bolus. Serum @entity53 concentrations were increased approximately 200% on the @entity172 (EST) compared with the control (CON) days. Serum insulin was reduced (P < 0.01) during stage 2 of the clamp for EST (63.3 +/- 12.8 micro U/ml) vs. CON (78.2 +/- 15.8 micro U/ml). Mean SSGIR and plasma @entity653 did not differ between CON and EST days. With adjustment for differences in insulin concentration between conditions, stage 2 @entity413 disposals were significantly higher (8.63 vs. 7.20 mg. kg-1. @entity1009 ) and plasma @entity653 concentrations were significantly lower (29.4 vs. 35.0 micro mol/l) for EST vs. CON. Our findings suggest that acute CE administration increases insulin clearance and action in postmenopausal @entity1 .
